Department of Hematology, Zhongshan Hospital of Xiamen University, Xiamen 361004, China.
Institute of Hematology, Fujian Union Hospital, Fuzhou, China.
Cancer Cell Int. 2012 Aug 23;12(1):38. doi: 10.1186/1475-2867-12-38.
Indolent lymphoma (IL), the second most common lymphoma, remains incurable with chemotherapy alone. While R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) remains the standard frontline regimen for diffuse Large B -cell lymphoma, the optimal chemotherapy regimen for frontline therapy of advanced IL remains uncertain. FCR (fludarabine, cyclophosphamide, rituximab) has been shown to be better than fludarabine alone and fludarabine plus cyclophosphamide for IL. In FOLL05 trial, R-CHOP was compared with R-CVP (cyclophosphamide, vincristine, prednisone) and R-FM (fludarabine, mitoxantrone). The study showed that R-CHOP appears to have the best risk-benefit ratio for IL. The StiL NHL1 trial showed that BR (bendamustine, rituximab) has longer progression free survival and is better tolerated than R-CHOP. Long-term complications with secondary malignancies between the two regimens appear to be comparable. In this review, new combination regimens reported at 2012 ASCO annual meeting were evaluated for frontline and salvage therapy of indolent lymphoma.
惰性淋巴瘤（IL）是第二常见的淋巴瘤，单独化疗仍然无法治愈。虽然 R-CHOP（利妥昔单抗、环磷酰胺、多柔比星、长春新碱、泼尼松）仍然是弥漫性大 B 细胞淋巴瘤的标准一线治疗方案，但对于晚期 IL 的一线治疗的最佳化疗方案仍不确定。FCR（氟达拉滨、环磷酰胺、利妥昔单抗）已被证明优于氟达拉滨单药和氟达拉滨联合环磷酰胺治疗 IL。在 FOLL05 试验中，R-CHOP 与 R-CVP（环磷酰胺、长春新碱、泼尼松）和 R-FM（氟达拉滨、米托蒽醌）进行了比较。该研究表明，R-CHOP 似乎对 IL 具有最佳的风险效益比。StiL NHL1 试验表明，BR（苯达莫司汀、利妥昔单抗）无进展生存期更长，且耐受性优于 R-CHOP。两种方案之间继发恶性肿瘤的长期并发症似乎相当。在这篇综述中，评估了 2012 年 ASCO 年会上报告的新联合治疗方案，以评估惰性淋巴瘤的一线和挽救治疗。
